An Alzheimer’s treatment from Eli Lilly and Co failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases of the mind-robbing condition that is notoriously difficult to treat.
The Indianapolis drugmaker’s announcement could be a step toward a long-awaited breakthrough in the fight against the disease.
However, researchers not tied to the studies — and Eli Lilly itself — cautioned against overreacting to the initial results.
Lilly said on Friday that its treatment, solanezumab, failed to slow the rate of cognitive decline, which involves a person’s ability to remember things, in two late-stage studies of about 1,000 patients each.
However, when data from the trials were combined, scientists saw a statistically significant slowing of that rate in the bigger population.
They also saw a statistically significant result when they examined a subgroup of patients with mild cases of Alzheimer’s disease. The studies focused on patients with mild to moderate Alzheimer’s cases.
Lilly officials would not discuss details of the results and said that they plan to talk with regulators about the next steps for the drug, which has yet to receive US Food and Drug Administration (FDA) approval. Full results from the studies will be presented at two scientific conferences in October. It is unclear how the FDA will view the results, given that the drug missed its main goals.
William H Thies, chief medical and scientific officer for the Alzheimer’s Association, which was not involved in Lilly’s research, said the statistical significance of the combined results is important.
“If that can be replicated, that is a major finding,” he said. “It’s the first time we’ve been able to change the course of Alzheimer’s disease or any part of Alzheimer’s disease in people.”
However, because the drug missed its main goals, Thies said the drug “is not going to the [FDA] tomorrow to be approved for sale.”
If you look through “rose-colored glasses” at the results, there may be a sign of potential benefit on cognitive tests, said Dr. Ronald Petersen, director of the Mayo Clinic’s Alzheimer’s Disease Research Center.
However, it is not clear whether that is enough to make a real difference clinically in how patients do, he said.
The key will be details the company will present later on brain imaging and other tests, he said.
“The danger would be an over-interpretation of a small finding or a subtle effect,” said Petersen, who heads a safety monitoring panel for two companies working on a different Alzheimer’s treatment.
About 35 million people worldwide have dementia, a term for brain disorders that affect memory, judgment and other mental functions. Alzheimer’s is the most common type. In the US, more than 5 million people have Alzheimer’s, which is the country’s sixth-leading cause of death.
Many Alzheimer’s patients typically live four to eight years after diagnosis, as the disease gradually erodes their memory and ability to think or perform simple tasks. Current Alzheimer’s treatments only temporarily ease symptoms such as memory loss, confusion and agitation. They do not slow, stop or reverse mental decline.
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price
NOT A PANACEA: Offering 5G services would not solve the problem of declining telecom incomes, chairman Sheih Chi-mau said, expecting a flat 5G telecom revenue Chunghwa Telecom Co (中華電信) yesterday became the nation’s first telecom to debut its 5G services, offering tiered tariffs that include a threshold of NT$599 and flat rates, as it aims to switch half of its subscribers to the 5G network within three years. Subscribers would have unlimited data transmission for monthly fees starting at NT$1,399 — the same flat rate as when the company launched its 4G service in 2014 — and they can subscribe to the highest-rate plan for NT$2,699 per month for faster data transmission speeds and larger bandwidth, the company said. Data transmission speeds would be within the range
STAYING AHEAD: TSMC expects its sales this year to grow 14 to 19 percent and could spend up to US$3.52 billion on research and development, leaving its rivals far behind Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) reported that the US last year approved 99 percent of its patent applications, which placed the tech giant among the top patent holders in the US. In its Corporate Social Responsibility Report, TSMC said it last year secured about 3,600 patents worldwide, including more than 2,300 in the US. As of the end of last year, TSMC owned more than 39,000 patents, the report said. The company last year filed almost 6,500 patent applications worldwide and ranked among the top 10 patent applicants in the US. In Taiwan, it was the largest patent applicant for the fourth